High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.

Published

Journal Article

More effective therapeutic strategies are required for patients with poor-prognosis systemic sclerosis (SSc). A phase 2 single-arm study of high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected hematopoietic cell transplantation (HCT) was conducted in 34 patients with diffuse cutaneous SSc. HDIT included total body irradiation (800 cGy) with lung shielding, cyclophosphamide (120 mg/kg), and equine antithymocyte globulin (90 mg/kg). Neutrophil and platelet counts were recovered by 9 (range, 7 to 13) and 11 (range, 7 to 25) days after HCT, respectively. Seventeen of 27 (63%) evaluable patients who survived at least 1 year after HDIT had sustained responses at a median follow-up of 4 (range, 1 to 8) years. There was a major improvement in skin (modified Rodnan skin score, -22.08; P < .001) and overall function (modified Health Assessment Questionnaire Disability Index, -1.03; P < .001) at final evaluation. Importantly, for the first time, biopsies confirmed a statistically significant decrease of dermal fibrosis compared with baseline (P < .001). Lung, heart, and kidney function, in general, remained clinically stable. There were 12 deaths during the study (transplantation-related, 8; SSc-related, 4). The estimated progression-free survival was 64% at 5 years. Sustained responses including a decrease in dermal fibrosis were observed exceeding those previously reported with other therapies. HDIT and autologous HCT for SSc should be evaluated in a randomized clinical trial.

Full Text

Duke Authors

Cited Authors

  • Nash, RA; McSweeney, PA; Crofford, LJ; Abidi, M; Chen, C-S; Godwin, JD; Gooley, TA; Holmberg, L; Henstorf, G; LeMaistre, CF; Mayes, MD; McDonagh, KT; McLaughlin, B; Molitor, JA; Nelson, JL; Shulman, H; Storb, R; Viganego, F; Wener, MH; Seibold, JR; Sullivan, KM; Furst, DE

Published Date

  • August 15, 2007

Published In

Volume / Issue

  • 110 / 4

Start / End Page

  • 1388 - 1396

PubMed ID

  • 17452515

Pubmed Central ID

  • 17452515

International Standard Serial Number (ISSN)

  • 0006-4971

Digital Object Identifier (DOI)

  • 10.1182/blood-2007-02-072389

Language

  • eng

Conference Location

  • United States